These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

313 related items for PubMed ID: 16503724

  • 1. Abciximab-associated thrombocytopenia after previous tirofiban-related thrombocytopenia.
    Dorsch MP, Montague D, Rodgers JE, Patterson C.
    Pharmacotherapy; 2006 Mar; 26(3):423-7. PubMed ID: 16503724
    [Abstract] [Full Text] [Related]

  • 2. Thrombocytopenia caused by abciximab or tirofiban and its association with clinical outcome in patients undergoing coronary stenting.
    Merlini PA, Rossi M, Menozzi A, Buratti S, Brennan DM, Moliterno DJ, Topol EJ, Ardissino D.
    Circulation; 2004 May 11; 109(18):2203-6. PubMed ID: 15117843
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Comparison of abciximab with "high-dose" tirofiban in patients undergoing percutaneous coronary intervention.
    Gunasekara AP, Walters DL, Aroney CN.
    Int J Cardiol; 2006 Apr 28; 109(1):16-20. PubMed ID: 16014315
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Impact of clinical syndrome acuity on the differential response to 2 glycoprotein IIb/IIIa inhibitors in patients undergoing coronary stenting: the TARGET Trial.
    Stone GW, Moliterno DJ, Bertrand M, Neumann FJ, Herrmann HC, Powers ER, Grines CL, Moses JW, Cohen DJ, Cohen EA, Cohen M, Wolski K, DiBattiste PM, Topol EJ.
    Circulation; 2002 May 21; 105(20):2347-54. PubMed ID: 12021219
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Delayed immune-mediated thrombocytopenia after re-exposure to abciximab therapy.
    Rasti M, Blostein M.
    Can J Cardiol; 2011 May 21; 27(6):869.e13-4. PubMed ID: 21885241
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Effect of glycoprotein IIb-IIIa receptor antagonism on platelet membrane glycoproteins after coronary stent placement.
    Gawaz M, Ruf A, Neumann FJ, Pogátsa-Murray G, Dickfeld T, Zohlnhöfer D, Schömig A.
    Thromb Haemost; 1998 Dec 21; 80(6):994-1001. PubMed ID: 9869173
    [Abstract] [Full Text] [Related]

  • 14. Emergency coronary artery bypass surgery in the era of glycoprotein IIb/IIIa receptor antagonist use.
    Pang JT, Fort S, Della Siega A, Cohen EA.
    J Card Surg; 2002 Dec 21; 17(5):425-31. PubMed ID: 12630543
    [Abstract] [Full Text] [Related]

  • 15. Acute profound thrombocytopenia following abciximab therapy.
    Bishara AI, Hagmeyer KO.
    Ann Pharmacother; 2000 Dec 21; 34(7-8):924-30. PubMed ID: 10928405
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Monitoring platelet function in glycoprotein IIB/IIIA inhibitor therapy.
    Wu KK, Willerson JT.
    Circulation; 2001 May 29; 103(21):2528-30. PubMed ID: 11382717
    [No Abstract] [Full Text] [Related]

  • 18. Clinical correlates and course of thrombocytopenia during percutaneous coronary intervention in the era of abciximab platelet glycoprotein IIb/IIIa blockade.
    Kereiakes DJ, Berkowitz SD, Lincoff AM, Tcheng JE, Wolski K, Achenbach R, Melsheimer R, Anderson K, Califf RM, Topol EJ.
    Am Heart J; 2000 Jul 29; 140(1):74-80. PubMed ID: 10874266
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.